ECCMID

ECCMID 2023: Shionogi Announces Real-World Evidence Demonstrating the Efficacy of Fetcroja® / Fetroja® (cefiderocol) Against Some of the Most Difficult-to-Treat Gram-Negative Bacterial Pathogens

Retrieved on: 
Monday, April 17, 2023
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Interim, University, Head, Consultant, Infection, AMR, Fungal infection, Cutis, Acinetobacter baumannii, Urinary tract infection, Pseudomonas aeruginosa, Congress, Death, Cefiderocol, ECCMID, Patient, European, Mortality, Intensive care medicine, Gram-negative bacteria, Salvage therapy, Pharmaceutical industry, Vaccine, EU, Shionogi

These were generally seriously ill patients, many requiring mechanical ventilation and/or vasopressor support.

Key Points: 
  • These were generally seriously ill patients, many requiring mechanical ventilation and/or vasopressor support.
  • Cefiderocol was initiated for a documented pathogen in the majority of cases (77%), and as monotherapy in 57% of patients.
  • Cefiderocol achieved clinical cure in 60% of patients, and 76% of patients were alive within 30-days of starting treatment.
  • Cefiderocol was targeted as first treatment or as salvage therapy in 93% of patients, and as monotherapy in 41% of patients.

Bugworks Research Inc. to Present Eight Posters at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2023, in Copenhagen, Denmark

Retrieved on: 
Monday, April 17, 2023
Infection, University of Texas Medical Branch, University, Survival, Research, University of Liverpool, Congress, WRAIR, ECCMID, IHMA, European, Walter Reed Army Institute of Research, Mouse, Pharmaceutical industry

and ADELAIDE, Australia, April 17, 2023 /PRNewswire/ -- Bugworks Research Inc., a clinical-stage biopharmaceutical company, is set to present its latest research findings on the novel bacterial topoisomerase inhibitor, BWC0977 at the upcoming 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark.

Key Points: 
  • and ADELAIDE, Australia, April 17, 2023 /PRNewswire/ -- Bugworks Research Inc., a clinical-stage biopharmaceutical company, is set to present its latest research findings on the novel bacterial topoisomerase inhibitor, BWC0977 at the upcoming 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark.
  • Bugworks Research is at the forefront of developing novel antibiotics to combat the growing threat of antimicrobial resistance.
  • The ECCMID conference is a leading global forum for infectious diseases and clinical microbiology.
  • Attendees are invited to visit the Bugworks Research booth to learn more about the company's innovative approach to fighting antibiotic resistance.

ECCMID 2023: Shionogi Announces Real-World Evidence Demonstrating the Efficacy of Fetcroja® (cefiderocol) Against Some of the Most Difficult-to-Treat Gram-Negative Bacterial Pathogens

Retrieved on: 
Monday, April 17, 2023
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Interim, University, Head, Consultant, Infection, AMR, Fungal infection, Cutis, Acinetobacter baumannii, Urinary tract infection, Pseudomonas aeruginosa, Congress, Death, Cefiderocol, ECCMID, Patient, European, Mortality, Intensive care medicine, Gram-negative bacteria, Salvage therapy, Pharmaceutical industry, Vaccine, EU, Shionogi

These were generally seriously ill patients, many requiring mechanical ventilation and/or vasopressor support.

Key Points: 
  • These were generally seriously ill patients, many requiring mechanical ventilation and/or vasopressor support.
  • Cefiderocol was initiated for a documented pathogen in the majority of cases (77%) and as monotherapy in 57% of patients.
  • Cefiderocol achieved clinical cure in 60% of patients, and 76% of patients were alive within 30-days of starting treatment.
  • Cefiderocol was targeted as first treatment or as salvage therapy in 93% of patients, and as monotherapy in 41% of patients.

Bugworks Research Inc. to Present Eight Posters at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2023, in Copenhagen, Denmark

Retrieved on: 
Monday, April 17, 2023
Infection, University of Texas Medical Branch, University, Survival, Research, University of Liverpool, Congress, WRAIR, ECCMID, IHMA, European, Walter Reed Army Institute of Research, Mouse, Pharmaceutical industry

and ADELAIDE, Australia, April 17, 2023 /PRNewswire/ -- Bugworks Research Inc., a clinical-stage biopharmaceutical company, is set to present its latest research findings on the novel bacterial topoisomerase inhibitor, BWC0977 at the upcoming 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark.

Key Points: 
  • and ADELAIDE, Australia, April 17, 2023 /PRNewswire/ -- Bugworks Research Inc., a clinical-stage biopharmaceutical company, is set to present its latest research findings on the novel bacterial topoisomerase inhibitor, BWC0977 at the upcoming 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark.
  • Bugworks Research is at the forefront of developing novel antibiotics to combat the growing threat of antimicrobial resistance.
  • The ECCMID conference is a leading global forum for infectious diseases and clinical microbiology.
  • Attendees are invited to visit the Bugworks Research booth to learn more about the company's innovative approach to fighting antibiotic resistance.

Veklury® (Remdesivir) Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations

Retrieved on: 
Sunday, April 16, 2023
Health, Infectious Diseases, Hospitals, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, Gilead Sciences, Omicron, Chronic kidney disease, Senior, Obeldesivir, Cancer, Pharmacokinetics, VOC, Kidney disease, Trial of the century, AKI, Plasma, Kidney, Acute kidney injury, Congress, ECCMID, MD, Patient, European, Risk, Science, Mortality, ESKD, Immunodeficiency, Death, CKD, Infection, Safety, Pharmaceutical industry, Remdesivir

A Phase 3 clinical study demonstrated that Veklury® (remdesivir) was generally well tolerated in people with moderate to severe renal impairment.

Key Points: 
  • A Phase 3 clinical study demonstrated that Veklury® (remdesivir) was generally well tolerated in people with moderate to severe renal impairment.
  • A separate real-world analysis demonstrated that use of Veklury is also associated with reduced hospital readmission risk in immunocompromised patients hospitalized with COVID-19.
  • “The breadth of clinical and real-world evidence data presented at ECCMID further support the strong efficacy and safety profile of Veklury,” said Frank Duff, MD, Senior Vice President, Virology Therapeutic Area Head, Gilead Sciences.
  • Gilead has advanced obeldesivir into two Phase 3 studies – BIRCH and OAKTREE – in broad populations and geographies to assess the efficacy and safety of obeldesivir for the treatment of non-hospitalized participants with COVID-19.

Spero Therapeutics to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases

Retrieved on: 
Friday, April 14, 2023
Defense, Research, Publication, Assistant, Infection, Pseudomonas aeruginosa, Congress, MDR, Spero, ECCMID, European, Key Publications, Rare, Therapy, Office of the Assistant Secretary for Health, Assistant Secretary of Defense for Health Affairs, Pharmaceutical industry

CAMBRIDGE, Mass., April 14, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced two poster presentations at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held April 15-18, 2023, in Copenhagen, Denmark.

Key Points: 
  • CAMBRIDGE, Mass., April 14, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced two poster presentations at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held April 15-18, 2023, in Copenhagen, Denmark.
  • The poster presentations at the ECCMID are as follows:
    Title: Activity of SPR206 and Comparator Agents Against Pseudomonas aeruginosa and Acintobacter spp.
  • Causing Infections in Europe and Adjacent Regions
    Spero Therapeutics’ ECCMID 2023 scientific exchange submissions can be found at Key Publications and Presentations on the Spero Therapeutics corporate website.
  • These research and poster presentations were sponsored by Spero Therapeutics, which was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Joint Warfighter Medical Research Program under Award No.

Bruker Introduces New Mycobacteria and Fungi IVD Solutions for MALDI Biotyper®, and a Novel LiquidArray® Gastrointestinal Syndromic Panel

Retrieved on: 
Friday, April 14, 2023
Technology, Medical Devices, Clinical Trials, Health Technology, Software, Other Health, Biotechnology, Hardware, Health, Consumer Electronics, Transfer, Infection, MVZ, MYT, Gastroenteritis, MALDI, BRKR, Workflow, HT, Mycobacterium, PCR, Multimedia, Temperature, Fungus, DK, Congress, Gastrointestinal tract, ECCMID, Nontuberculous mycobacteria, Partner, XT, Laboratory, European, IVD, MBT, Microbiology, Bruker, Vaccine, Medical device

The new MBT Mycobacteria IVD Kit offers a user-friendly, dedicated sample preparation method for mycobacteria cultivated in liquid as well as on solid media.

Key Points: 
  • The new MBT Mycobacteria IVD Kit offers a user-friendly, dedicated sample preparation method for mycobacteria cultivated in liquid as well as on solid media.
  • The MBT Mycobacteria IVD Kit further simplifies the workflow for identification of nontuberculous mycobacteria by MALDI-TOF MS and reduces hands-on time.
  • The new LiquidArray® Gastrointestinal is a syndromic panel that enables the simultaneous detection of up to 26 pathogens causing gastroenteritis.
  • The new LiquidArray® Gastrointestinal is a next-generation syndromic panel with amazing pathogen coverage.

Co-Diagnostics, Inc. to Host Booth at ECCMID 2023 April 15-18 in Copenhagen, Denmark

Retrieved on: 
Thursday, April 13, 2023
Learning, Infection, SALT, Sale, Congress, ECCMID, European, FDA, PCR, Pharmaceutical industry

ECCMID is described as one of the most comprehensive and influential congresses in infectious diseases, bringing together international experts in related fields to present their latest findings, guidelines and experiences to an audience of over 14,000 colleagues.

Key Points: 
  • ECCMID is described as one of the most comprehensive and influential congresses in infectious diseases, bringing together international experts in related fields to present their latest findings, guidelines and experiences to an audience of over 14,000 colleagues.
  • The congress also features a hybrid format, to facilitate an onsite and online experience for attendees allowing for remote and face-to-face opportunities.
  • Attendees interested in learning more about the Company, including its upcoming Co-Dx PCR Home™ platform, are invited to visit Booth B4-04.
  • The Co-Dx PCR Home is subject to FDA review and is not available for sale.

Theriva Biologics Announces Presentation of Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Retrieved on: 
Thursday, April 13, 2023
Therapy, Date-time group, Cancer, HCT, Congress, Date, ECCMID, MD, European, CEST, Washington University School of Medicine, Poster, NYSE, Infection, Safety, Pharmaceutical industry

ROCKVILLE, Md., April 13, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the presentation of the previously disclosed blinded safety and pharmacokinetic (PK) data from the ongoing Phase 1b/2a randomized, double-blinded, placebo-controlled clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients for the prevention of acute graft-versus-host-disease (aGVHD).

Key Points: 
  • ROCKVILLE, Md., April 13, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the presentation of the previously disclosed blinded safety and pharmacokinetic (PK) data from the ongoing Phase 1b/2a randomized, double-blinded, placebo-controlled clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients for the prevention of acute graft-versus-host-disease (aGVHD).
  • These data will be featured in a poster presentation at 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), being held virtually and in-person in Copenhagen, Denmark from April 15-18, 2023.
  • Details on the poster (#P2280) can be found below.
  • Presenting Author: Erik R. Dubberke, MD, Professor of Medicine, Clinical Director, Transplant Infectious Diseases, Washington University School of Medicine in St. Louis
    Session: (5c) New or repurposed antibacterial agents: clinical studies and trials
    Date & Time: Monday, April 17 at 12:00 p.m. CEST
    Location: Virtually through the online conference platform and in person at the Bella Centre Copenhagen, Denmark.

SCYNEXIS to Present Ibrexafungerp Data at the 33rd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) April 15-18 in Denmark

Retrieved on: 
Thursday, April 13, 2023
Urinary tract infection, Infection, Biotechnology, Candida auris, Congress, Antimalarial medication, ECCMID, European, FURI, Pharmaceutical industry

surveillance)

Key Points: 
  • surveillance)
    Poster Session 6D: Antifungal drugs & treatment (incl.
  • clinical trials)
    Poster Session 6D: Antifungal drugs & treatment (incl.
  • clinical trials)
    Poster Session 6D: Antifungal drugs & treatment (incl.
  • clinical trials)